The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roberta Schwartz, Ph.D., the health system’s executive vice president and chief innovation officer, describes efficiencies gained from the new system
We’re in the middle of a fundamental shift that’s giving consumers more power and choice over their health coverage while creating healthy competition in the marketplace. Consumer expectations are justifiably rising, and people want a much more pleasant, frictionless and digital experience from their health plan – just like they get everyplace else in their…
[Sponsored] An upcoming webinar sponsored by Solera Health will explore how employers can develop benefit strategies that improve employee outcomes and fit their budgets. The post What Self-Insured Employers Should Look for in a Digital Health Vendor appeared first on MedCity News.
San Francisco – KFF announced today that Dr. Dave Ashok Chokshi, a practicing physician and health leader, has joined KFF’s Board of Trustees. Dr. Chokshi is a physician at Bellevue Hospital as well as Sternberg Family Professor of Leadership at the City College of New York.